/ACRS

Aclaris Therapeutics Inc

ACRS

$6.05USD↑+0.67%+0.04 today

MARKET CAP

890.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$6 – $6

52W RANGE

$2

$7

AI Summary

Stalk

StalkMedium

ACRS remains in a Stage 2 advancing regime with higher highs and rising EMAs intact. The medium-term bias is bullish, reinforced by price above key moving averages despite exhaustion signals. Near-term, a Bullish Exhaustion pattern and RSI pullback indicate momentum is easing. Price is consolidating just above the 9/20 EMA band, making timing unfavorable now. Wait for a pullback into rising EMA support before initiating any long exposure.

↑ATI-2138 advanced into a proof-of-concept study for moderate-to-severe atopic dermatitis.
↑Piper Sandler assigns a Buy rating, signaling positive analyst sentiment on clinical data.
↓Q2 2026 net loss grew to $21.5M from $15.4M year-ago, straining margins.

Full analysis →

Buying

3

institutions

Selling

7

institutions

New Positions

0

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕	Action↕	Shares Held↕	Value↓	Change↕	Chg %↕	Weight↕
RC Ra Capital Management, L.P. Q2 2026	BUY	12.72 M	67.30 M	+5.92 M	+163.8%	0.59%
BI Blackrock, Inc. Q2 2026	BUY	10.04 M	53.10 M	+2.63 M	+91.2%	0.00%
CA Citadel Advisors LLC Q2 2026	SELL	2.39 M	12.63 M	+-430.94 K	+19.5%	0.00%
BA Balyasny Asset Management L.P. Q2 2026	SELL	2.02 M	10.70 M	+-1.34 M	-15.1%	0.01%
WP Woodline Partners LP Q2 2026	SELL	1.61 M	8.52 M	+-1.36 M	-23.5%	0.03%
RT Renaissance Technologies LLC Q2 2026	BUY	817.53 K	4.32 M	+314.90 K	+129.4%	0.01%
MM Millennium Management LLC Q2 2026	SELL	523.89 K	2.77 M	+-232.23 K	-2.3%	0.00%
JC Jpmorgan Chase & Co Q2 2026	SELL	468.96 K	2.35 M	+-17.67 K	+38.6%	0.00%
AC Aqr Capital Management LLC Q2 2026	SELL	60.26 K	318.77 K	+-12.15 K	+17.4%	0.00%
AC Adar1 Capital Management, LLC Q2 2026	SELL	0.00	0.00	+-132.43 K	-100.0%	0.00%